SeeThruEquity Initiates Research Coverage on AtheroNova, Inc.

NEW YORK--()--SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on AtheroNova, Inc. (OTCQB: AHRO), a biotechnology company focused on the discovery, research, development and licensing of novel compounds to safely reduce or regress atherosclerotic plaque deposits and improve lipid profiles in humans.

“Cardiovascular disease presents a tremendous end market and AtheroNova is uniquely positioned to capture significant market share,” stated Ajay Tandon, Chief Executive Officer of SeeThruEquity. He further commented, “Assuming FDA approval, potential market sectors addressed by AHRO’s lead drug, AHRO-001, include cardiovascular disease, stroke and peripheral artery disease, all of which have been linked to atherosclerosis. The number of patients addressed is well north of 86 million and the market size is more than $41 billion in the U.S. alone. Given these factors and others, our analysis indicates a fair value estimate of $1.03 per share for AHRO.”

The report is available to SeeThruEquity Select Members on SeeThruEquity's website at http://www.seethruequity.com and can be directly accessed here: AHRO Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, CapitalIQ, FactSet, and Zack’s. The report will also available on these platforms.

The investment opinions expressed in its report are solely those of SeeThruEquity. SeeThruEquity has not been compensated for the preparation of its initiation or quarterly update reports by any third party or by AHRO. SeeThruEquity has been compensated for the preparation and dissemination of this press release.

About SeeThruEquity

SeeThruEquity is an investment research and corporate access firm focused on smallcap and microcap public companies. The research is unbiased and not paid for research. The company does not do any investment banking or trading and does not own any of the stocks it covers. SeeThruEquity is an approved equity research contributor on Thomson First Call, CapitalIQ, FactSet, and Zack’s. The firm also distributes its research to an audience of opt-in investors and has over 50 companies under coverage. SeeThruEquity also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street. For more information visit www.seethruequity.com.

About AtheroNova, Inc.

AtheroNova Inc. is a biotechnology company focused on the discovery, research, development and licensing of novel compounds to safely reduce or regress atherosclerotic plaque deposits and improve lipid profiles in humans. In addition to its lead compound AHRO-001, AtheroNova plans to develop multiple applications for its patented and patents-pending therapies in market sectors that include: Cardiovascular Disease, Stroke and Peripheral Artery Disease, all of which have been linked to atherosclerosis. Atherosclerosis and its related pharmaceutical expenses for these indications cost consumers more than $41 billion annually in the United States alone. For more information, please visit www.AtheroNova.com.

Contacts

SeeThruEquity
Ajay Tandon
(646) 495-0939

Sharing

Contacts

SeeThruEquity
Ajay Tandon
(646) 495-0939